| AIM IMMUNOTECH |
| USA |
| Gesundheit |
| US00901B3033 / A416YS |
| HXB (Frankfurt) |
| FRA:HXB, ETR:HXB, HXB:GR |
| - |
| https://aimimmuno.com/ |
|
AIM ImmunoTech Inc. is a biotechnology and immuno-pharmaceutical company specializing in the development of novel therapeutics for multiple cancers, immune disorders, and viral infections including COVID-19. Its flagship product, Ampligen®, is an RN..
>Volltext.. |
| 3.88 Mio. EUR |
| 5.48 Mio. EUR |
| 0.08 Mio. EUR |
| -8.94 Mio. EUR |
| -12.09 Mio. EUR |
| -10.28 EUR |
| 4.24 Mio. EUR |
| 2.59 Mio. EUR |
| -9.49 Mio. EUR |
| 0.49 |
| -48.24% |
| 19.41% |
| - |
| - |
| - |
| - |
| AIM IMMUNOTECH, AIM IMMUNO |
| 05.04.26 |
|